ArticleGut1998
Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation.
Article in Gut, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 213 citations in OpenAlex.
- The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis.International journal of colorectal disease · 2011Pooled it
- Dynamics of a cytokine storm.PloS one · 2012Trial
- Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes.Digestive diseases and sciences · 2007Trial
- Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.World journal of gastroenterology · 2006Trial
- Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.Digestive diseases and sciences · 2004Trial
- Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial.Therapeutic advances in gastroenterology · 2026Article
- First Description of Simultaneous Sweet Syndrome and Tracheal Stenosis as Extraintestinal Manifestations in a Patient With Highly Active Ulcerative Colitis.ACG case reports journal · 2025Article
- Differential activation of monocytes and PMNs in orofacial granulomatosis patients induced by bacterial and non-bacterial stimuli.Frontiers in immunology · 2025Article
- Article
- Article
- Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.Frontiers in immunology · 2023Review
- Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis.Biomaterials · 2022Article
- Detailed Transcriptional Landscape of Peripheral Blood Points to Increased Neutrophil Activation in Treatment-Naïve Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2022Article
- Fruits ofFrontiers in pharmacology · 2022Article
- Aspartate Metabolism Facilitates IL-1β Production in Inflammatory Macrophages.Frontiers in immunology · 2021Article
- Macrophage polarization in intestinal inflammation and gut homeostasis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- The relationship between preoperative T helper cytokines in the ileal mucosa and the pathogenesis of pouchitis.BMC gastroenterology · 2020Article
- Acyclic Triterpenoid Isolated fromMolecules (Basel, Switzerland) · 2020Article
- Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases.Intestinal research · 2020Review
- LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS.Acta clinica Croatica · 2019Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcentrations of pro-inflammatory cytokines are increased in the intestinal mucosa of patients with active inflammatory bowel disease (IBD). Polymorphonuclear neutrophil granulocytes (PMN) are the most abundant cell type in intestinal lesions in IBD. Interleukin 10 (IL-10) is an important contra-inflammatory cytokine which induces downregulation of pro-inflammatory cytokines.
aimsTo investigate whether PMN from patients with IBD or infectious colitis, respectively, secrete increased amounts of pro-inflammatory cytokines and can be regulated by IL-10.
methodsSecretion (ELISA) as well as corresponding mRNA levels (semiquantitative RT-PCR) of pro-inflammatory cytokines (IL-1 beta, TNF-alpha) and of IL-1 receptor antagonist were assessed in peripheral PMN.
resultsPMN from patients with IBD are primed to secrete enhanced amounts of pro-inflammatory cytokines accompanied by detection of corresponding mRNAs in comparison with normal controls. This finding is not specific for IBD but rather reflects intestinal inflammation in general. IL-10 markedly inhibited proinflammatory cytokine secretion as well as corresponding mRNA concentrations.
conclusionsPMN are an important source of pro-inflammatory cytokines in patients with intestinal inflammation and can be downregulated by IL-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.